Proteogenomics meets cancer immunology: Mass spectrometric discovery and analysis of neoantigens

Expert Review of Proteomics

Volumn 12, Issue 5, 2015, Pages 533-541

  Polyakova, Anna ^a   Kuznetsova, Ksenia ^a   Moshkovskii, Sergei ^a  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

cancer genome; cytotoxic T lymphocyte; major histocompatibility complex; mass spectrometry; neoantigen; proteogenomics; T cell epitope

Indexed keywords

ANTIGEN; CANCER VACCINE; NEOANTIGEN; PEPTIDE; PROTEOME; UNCLASSIFIED DRUG; TUMOR ANTIGEN;

CANCER IMMUNOLOGY; GENE IDENTIFICATION; GENETIC CODE; GENETIC VARIABILITY; GENOMICS; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; MASS SPECTROMETRY; MEDICINE; NONHUMAN; PROTEIN ANALYSIS; PROTEOGENOMICS; PROTEOMICS; REVIEW; TREATMENT RESPONSE; ANIMAL; CHEMISTRY; GENETICS; IMMUNOLOGY; NEOPLASM; PROCEDURES;

ANIMALS; ANTIGENS, NEOPLASM; HUMANS; MASS SPECTROMETRY; NEOPLASMS; PROTEOME;

EID: 84942432586     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.2015.1070100     Document Type: Review

References (65)

1. Archakov A, Lisitsa A, Ponomarenko E, et al. Recent advances in proteomic profiling of human blood: clinical scope. Expert Rev Proteomics 2015; 12 (2): 111-13
2. Oliver GR, Hart SN, Klee EW. Bioinformatics for clinical next generation sequencing. Clin Chem 2015; 61 (1): 124-35
3. Lisitsa A, Moshkovskii S, Chernobrovkin A, et al. Profiling proteoforms: promising follow-up of proteomics for biomarker discovery. Expert Rev Proteomics 2014; 11 (1): 121-9
4. Aebersold R, Burlingame AL, Bradshaw RA. Western blots versus selected reaction monitoring assays: time to turn the tables? Mol Cell Proteomics 2013; 12 (9): 2381-2
5. Lin D, Alborn WE, Slebos RJ, et al. Comparison of protein immunoprecipitation-multiple reaction monitoring with ELISA for assay of biomarker candidates in plasma. J Proteome Res 2013; 12 (12): 5996-6003
6. Schoenherr RM, Saul RG, Whiteaker JR, et al. Anti-peptide monoclonal antibodies generated for immuno-multiple reaction monitoring-mass spectrometry assays have a high probability of supporting Western blot and ELISA. Mol Cell Proteomics 2015; 14 (2): 382-98
7. Kelleher NL, Thomas PM, Ntai I, et al. Deep and quantitative top-down proteomics in clinical and translational research. Expert Rev Proteomics 2014; 11 (6): 649-51
8. Wolters DA, Washburn MP, Yates JR III. An automated multidimensional protein identification technology for shotgun proteomics. Anal Chem 2001; 73 (23): 5683-90
9. Schmidt A, Gehlenborg N, Bodenmiller B, et al. An integrated, directed mass spectrometric approach for in-depth characterization of complex peptide mixtures. Mol Cell Proteomics 2008; 7 (11): 2138-50
10. Webber J, Stone TC, Katilius E, et al. Proteomics analysis of cancer exosomes using a novel modified aptamer-based array (SOMAscan™) platform. Mol Cell Proteomics 2014; 13 (4): 1050-64
11. Stave JW, Lindpaintner K. Antibody and antigen contact residues define epitope and paratope size and structure. J Immunol 2013; 191 (3): 1428-35
12. Lawrence MS, Stojanov P, Mermel CH, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014; 505 (7484): 495-501
13. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015; 348 (6230): 69-74
14. Zhang B, Pirmoradian M, Chernobrovkin A, et al. DeMix workflow for efficient identification of cofragmented peptides in high resolution data-dependent tandem mass spectrometry. Mol Cell Proteomics 2014; 13 (11): 3211-23
15. Hao P, Ren Y, Alpert AJ, et al. Detection, evaluation and minimization of nonenzymatic deamidation in proteomic sample preparation. Mol Cell Proteomics 2011; 10 (10): O111.009381
16. Chernobrovkin AL, Kopylov AT, Zgoda VG, et al. Methionine to isothreonine conversion as a source of false discovery identifications of genetically encoded variants in proteogenomics. J Proteomics 2015; 120: 169-78
17. Jaffe JD, Berg HC, Church GM. Proteogenomic mapping as a complementary method to perform genome annotation. Proteomics 2004; 4 (1): 59-77
18. Nesvizhskii AI. Proteogenomics: concepts, applications and computational strategies. Nat Methods 2014; 11 (11): 1114-25
19. Manda SS, Nirujogi RS, Pinto SM, et al. Identification and characterization of proteins encoded by chromosome 12 as part of chromosome-centric human proteome project. J Proteome Res 2014; 13 (7): 3166-77
20. Kucharova V, Wiker HG. Proteogenomics in microbiology: taking the right turn at the junction of genomics and proteomics. Proteomics 2014; 14 (23-24): 2360-675
21. Ansong C, Purvine SO, Adkins JN, et al. Proteogenomics: needs and roles to be filled by proteomics in genome annotation. Brief Funct Genomic Proteomic 2008; 7 (1): 50-62
22. Karpova MA, Karpov DS, Ivanov MV, et al. Exome-driven characterization of the cancer cell lines at the proteome level: the NCI-60 case study. J Proteome Res 2014; 13 (12): 5551-60
23. Zhao HQ, Zhang P, Gao H, et al. Profiling the RNA editomes of wild-Type C. elegans and ADAR mutants. Genome Res 2015; 25 (1): 66-75
24. Menon R, Im H, Zhang EY, et al. Distinct splice variants and pathway enrichment in the cell-line models of aggressive human breast cancer subtypes. J Proteome Res 2014; 13 (1): 212-27
25. Alfaro JA, Sinha A, Kislinger T, et al. Onco-proteogenomics: cancer proteomics joins forces with genomics. Nat Methods 2014; 11 (11): 1107-13
26. Forbes SA, Beare D, Gunasekaran P, et al. COSMIC: exploring the worlds knowledge of somatic mutations in human cancer. Nucleic Acids Res 2015; 43: D805-11
27. Li J, Su Z, Ma ZQ, et al. A bioinformatics workflow for variant peptide detection in shotgun proteomics. Mol Cell Proteomics 2011; 10 (5): M110.006536
28. Abaan OD, Polley EC, Davis SR, et al. The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res 2013; 73 (14): 4372-82
29. Moghaddas Gholami A, Hahne H, Wu Z, et al. Global proteome analysis of the NCI-60 cell line panel. Cell Rep 2013; 4 (3): 609-20
30. Elias JE, Gygi SP. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat Methods 2007; 4 (3): 207-14
31. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515 (7528): 568-71
32. Mueller KL. Cancer immunology and immunotherapy. Realizing the promise. Introduction. Science 2015; 348 (6230): 54-5
33. Blankenstein T, Leisegang M, Uckert W, et al. Targeting cancer-specific mutations by T cell receptor gene therapy. Curr Opin Immunol 2015; 33: 112-19
34. Admon A, Barnea E, Ziv T. Tumor antigens and proteomics from the point of view of the major histocompatibility complex peptides. Mol Cell Proteomics 2003; 2 (6): 388-98
35. Santambrogio L, Sato AK, Fischer FR, et al. Abundant empty class II MHC molecules on the surface of immature dendritic cells. Proc Natl Acad Sci USA 1999; 96 (26): 15050-5
36. Mendez R, Aptsiauri N, Del Campo A, et al. HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank. Cancer Immunol Immunother 2009; 58 (9): 1507-15
37. Li XC, Raghavan M. Structure and function of major histocompatibility complex class I antigens. Curr Opin Organ Transplant 2010; 15 (4): 499-504
38. Soria-Guerra RE, Nieto-Gomez R, Govea-Alonso DO, et al. An overview of bioinformatics tools for epitope prediction: implications on vaccine development. J Biomed Inform 2015; 53: 405-14
39. Hoof I, Peters B, Sidney J, et al. NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics 2009; 61 (1): 1-13
40. Lin HH, Zhang GL, Tongchusak S, et al. Evaluation of MHC-II peptide binding prediction servers: applications for vaccine research. BMC Bioinformatics 2008; 9 (Suppl 12): S22
41. Immune epitope database and analysis resource. Available from: www.iedb.org
42. SYFPEITHI, A database of mhc ligands and peptide motifs (Ver. 1.0). Available from: www.syfpeithi.de
43. Klein J. Seeds of time: fifty years ago Peter A. Gorer discovered the H-2 complex. Immunogenetics 1986; 24 (6): 331-8
44. Hunt DF, Henderson RA, Shabanowitz J, et al. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992; 255 (5049): 1261-3
45. Purcell AW, Gorman JJ. Immunoproteomics: Mass spectrometry-based methods to study the targets of the immune response. Mol Cell Proteomics 2004; 3 (3): 193-208
46. Galati G, Arcelloni C, Paroni R, et al. Quantitative cytometry of MHC class I digestion from living cells. Cytometry 1997; 27 (1): 77-83
47. Antwi K, Hanavan PD, Myers CE, et al. Proteomic identification of an MHC-binding peptidome from pancreas and breast cancer cell lines. Mol Immunol 2009; 46 (15): 2931-7
48. Dengjel J, Schoor O, Fischer R, et al. Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. Proc Natl Acad Sci USA 2005; 102 (22): 7922-7
49. Schirle M, Keilholz W, Weber B, et al. Identification of tumor-Associated MHC class I ligands by a novel T cell-independent approach. Eur J Immunol 2000; 30 (8): 2216-25
50. Falk K, Rötzschke O, Stevanović S, et al. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991; 351 (6324): 290-6
51. Andrews MC, Woods K, Cebon J, et al. Evolving role of tumor antigens for future melanoma therapies. Future Oncol 2014; 10 (8): 1457-68
52. Jarmalavicius S, Welte Y, Walden P. High immunogenicity of the human leukocyte antigen peptidomes of melanoma tumor cells. J Biol Chem 2012; 287 (40): 33401-11
53. Demine R, Walden P. Sequit: software for de novo peptide sequencing by matrix-Assisted laser desorption/ionization post-source decay mass spectrometry. Rapid Commun Mass Spectrom 2004; 18 (8): 907-13
54. Pritchard AL, Hastie ML, Neller M, et al. Exploration of peptides bound to MHC class I molecules in melanoma. Pigment Cell Melanoma Res 2015; 28 (3): 281-94
55. Zhang B, Wang J, Wang X, et al. Proteogenomic characterization of human colon and rectal cancer. Nature 2014; 513 (7518): 382-7
56. Yadav M, Jhunjhunwala S, Phung QT, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 2014; 515 (7528): 572-6
57. Gubin MM, Zhang X, Schuster H, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014; 515 (7528): 577-81
58. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348 (6230): 124-8
59. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371 (23): 2189-99
60. Guo T, Kouvonen P, Koh CC, et al. Rapid mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital proteome maps. Nat Med 2015; 21 (4): 407-13
61. Richards AL, Hebert AS, Ulbrich A, et al. One-hour proteome analysis in yeast. Nat Protoc 2015; 10 (5): 701-14
62. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 2015; 348 (6230): 62-8
63. Mac Keon S, Ruiz MS, Gazzaniga S, Wainstok R. Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models. Front Immunol 2015; 6: 243
64. McFarland CD, Korolev KS, Kryukov GV, et al. Impact of deleterious passenger mutations on cancer progression. Proc Natl Acad Sci USA 2013; 110: 2910-15
65. Carreno BM, Magrini V, Becker-Hapak M, et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 2015; 348: 803-8